CN107922349A - 作为fgfr和vegfr抑制剂的乙烯基化合物 - Google Patents

作为fgfr和vegfr抑制剂的乙烯基化合物 Download PDF

Info

Publication number
CN107922349A
CN107922349A CN201680046188.0A CN201680046188A CN107922349A CN 107922349 A CN107922349 A CN 107922349A CN 201680046188 A CN201680046188 A CN 201680046188A CN 107922349 A CN107922349 A CN 107922349A
Authority
CN
China
Prior art keywords
milliliters
milligrams
crr
grams
lcms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680046188.0A
Other languages
English (en)
Other versions
CN107922349B (zh
Inventor
陈曙辉
陈正霞
戴美碧
谢程
李鹏
张杨
梁贵柏
王强
廖江鹏
孙飞
胡国平
黎健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin Zhenbao Pharmaceutical Co ltd
Original Assignee
Harbin Zhenbao Pharmaceutical Co ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin Zhenbao Pharmaceutical Co ltd, Medshine Discovery Inc filed Critical Harbin Zhenbao Pharmaceutical Co ltd
Publication of CN107922349A publication Critical patent/CN107922349A/zh
Application granted granted Critical
Publication of CN107922349B publication Critical patent/CN107922349B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

提供一种FGFR和VEGFR抑制剂，具体公开了作为FGFR和VEGFR抑制剂的式(I)或(Ⅱ)所示化合物、药学上可接受的盐或其互变异构体。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201680046188.0A 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物 Active CN107922349B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510484124 2015-08-07
CN2015104841246 2015-08-07
CN2015109080824 2015-12-09
CN201510908082 2015-12-09
PCT/CN2016/092989 WO2017024968A1 (zh) 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物

Publications (2)

Publication Number Publication Date
CN107922349A true CN107922349A (zh) 2018-04-17
CN107922349B CN107922349B (zh) 2021-05-07

Family

ID=57983012

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680046188.0A Active CN107922349B (zh) 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物

Country Status (5)

Country Link
US (1) US10519133B2 (zh)
EP (1) EP3333157B1 (zh)
JP (1) JP6898306B2 (zh)
CN (1) CN107922349B (zh)
WO (1) WO2017024968A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6803410B2 (ja) * 2017-02-14 2020-12-23 富士フイルム株式会社 インダゾール化合物の製造方法およびインダゾール化合物
CN116283940A (zh) * 2017-12-07 2023-06-23 哈尔滨珍宝制药有限公司 一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法
CN113490667B (zh) * 2018-12-29 2023-10-27 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
EP3919478A4 (en) * 2019-02-02 2022-12-07 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. VINYLPYRIDINE CARBOXAMIDE COMPOUND USEFUL AS A PD-L1 IMMUNOMODULATOR
AU2020214518B2 (en) * 2019-02-02 2022-12-15 Novaonco Js Therapeutics Co., Ltd. Fluorovinylbenzamide compound as PD-L1 immunomodulator
CN113993867B (zh) * 2019-06-14 2023-10-24 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物
CN114072387B (zh) * 2019-11-06 2024-03-08 暨南大学 吲唑类化合物及其药用组合物和应用
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
JP2023536603A (ja) * 2020-08-11 2023-08-28 ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド Ｆｇｆｒ阻害剤化合物及びその使用
US20240109865A1 (en) * 2020-12-30 2024-04-04 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
WO2023279041A1 (en) * 2021-06-30 2023-01-05 Tyra Biosciences, Inc. Indazole compounds
WO2024006897A1 (en) * 2022-06-29 2024-01-04 Tyra Biosciences, Inc. Indazole compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (en) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
US20030207883A1 (en) * 2001-07-03 2003-11-06 Chiron Corporation Indazole benzimidazole compounds
CN1747950A (zh) * 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2－(1h－吲唑－6－基氨基)－苯甲酰胺化合物
US20060058366A1 (en) * 2002-12-03 2006-03-16 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
CN102421769A (zh) * 2009-05-07 2012-04-18 伊莱利利公司 乙烯基吲唑基化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010137A1 (en) * 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EA006711B1 (ru) 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (en) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
WO2002010137A2 (en) * 2000-07-31 2002-02-07 Signal Pharmaceuticals, Inc. Indazole derivatives as jnk inhibitors
US20030207883A1 (en) * 2001-07-03 2003-11-06 Chiron Corporation Indazole benzimidazole compounds
US20060058366A1 (en) * 2002-12-03 2006-03-16 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitor
CN1747950A (zh) * 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2－(1h－吲唑－6－基氨基)－苯甲酰胺化合物
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
CN102421769A (zh) * 2009-05-07 2012-04-18 伊莱利利公司 乙烯基吲唑基化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STÉPHANIE BLANCHARD ET AL.: "Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
YONGLIU ET AL.: "The Discovery of Orally Bioavailable Tyrosine Threonine Kinase(TTK) Inhibitors:3-(4-(heterocyclyl) phenyl) -1H-indazole-5-carboxamidesas Anticancer Agents", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
EP3333157B1 (en) 2020-12-23
WO2017024968A1 (zh) 2017-02-16
EP3333157A1 (en) 2018-06-13
US10519133B2 (en) 2019-12-31
CN107922349B (zh) 2021-05-07
US20180222886A1 (en) 2018-08-09
JP2018531218A (ja) 2018-10-25
JP6898306B2 (ja) 2021-07-07
EP3333157A4 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
CN107922349A (zh) 作为fgfr和vegfr抑制剂的乙烯基化合物
US11021465B2 (en) DNA-PK inhibitors
CA2927392C (en) Dna-pk inhibitors
CN107428731A (zh) 作为抗癌药物的取代的2‑氢‑吡唑衍生物
JP2018531218A6 (ja) Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
CN107683279A (zh) 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
AU2014337208A1 (en) DNA-PK inhibitors
CN107614498A (zh) 二氮杂‑苯并荧蒽类化合物
US10654868B2 (en) Dihydropyrazole azepine compound serving as Akt inhibitor
CN109952290A (zh) Fgfr4 抑制剂及其制备方法和应用
CN105985333A (zh) 二氮杂-苯并荧蒽类化合物
CN116981458A (zh) 具有四氢吲哚-1-甲酰胺作为bcl-2抑制剂的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 150060 Heilongjiang city of Harbin province Harbin Development Zone Road haping road centralized District No. 8 Yantai

Applicant after: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 150060 Heilongjiang city of Harbin province Harbin Development Zone Road haping road centralized District No. 8 Yantai

Applicant before: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Applicant before: MEDSHINE DISCOVERY Inc.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20200628

Address after: 150060 Heilongjiang city of Harbin province Harbin Development Zone Road haping road centralized District No. 8 Yantai

Applicant after: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Address before: 150060 Heilongjiang city of Harbin province Harbin Development Zone Road haping road centralized District No. 8 Yantai

Applicant before: HARBIN ZHENBAO PHARMACEUTICAL Co.,Ltd.

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant